Director John James Sullivan filed a Form 4 with the SEC on August 17, 2026, disclosing the sale of 7,093 shares of Mesa Laboratories Inc common stock on August 13, 2026, in a private transaction with the company's President and CEO.

Key Highlights

  • Shares sold: Sullivan disposed of 7,093 shares of common stock on August 13, 2026, at a price of $112.8 per share.
  • Private transaction: According to the filing, the shares were sold directly in a private transaction to Siddhartha Kadia, Mesa's President and CEO.
  • Direct ownership after sale: Sullivan directly holds 17,834 shares following the reported transaction.
  • Trust holdings: An additional 45,110 shares are held indirectly through the Sullivan Family Trust, of which the reporting person's spouse serves as trustee.
  • Beneficial ownership disclaimer: The filing states Sullivan "disclaims beneficial ownership of the securities held by the trust except to the extent of his pecuniary interest therein."
  • Filing signed under Power of Attorney: The form was signed by John Sakys under Power of Attorney on behalf of John Sullivan on August 17, 2026.

Sullivan's Share Sale to Mesa CEO at $112.8 Per Share

According to the Form 4 filed with the SEC, John James Sullivan, a director of Mesa Laboratories Inc /CO/ (NASDAQ:MLAB), sold 7,093 shares of common stock on August 13, 2026, at a price of $112.8 per share. The filing identifies the transaction code as "S" and classifies the shares as disposed of (D). Notably, the filing discloses that this was a private transaction conducted directly with Siddhartha Kadia, described as Mesa's President and CEO.

Following the reported sale, Sullivan holds 17,834 shares of common stock directly. In addition, 45,110 shares are reported as indirectly held through the Sullivan Family Trust. The filing notes that the reporting person's spouse serves as trustee of that trust, and that Sullivan disclaims beneficial ownership of those trust-held shares except to the extent of his pecuniary interest. No derivative securities transactions were reported in Table II of the filing.

The Form 4 was filed on August 17, 2026, with the earliest transaction date listed as August 13, 2026. The document was signed by John Sakys under a Power of Attorney granted by John Sullivan. Sullivan's address is listed as 12100 W. 6th Avenue, Lakewood, Colorado 80228.

What Was Disclosed

The filing disclosed a single disposition of 7,093 shares of Mesa Laboratories common stock by director John James Sullivan in a private sale to the company's President and CEO at $112.8 per share, with Sullivan retaining 17,834 direct shares and 45,110 indirect shares held through a family trust.